Opzelura (ruxolitinib cream) / Incyte, Maruho, China Medical System, Dermavon, Specialised Therap - LARVOL DELTA

Talaromyces marneffei Infection Mimicking Refractory Pyoderma Gangrenosum in Ulcerative Colitis on Combination Immunosuppression (ACG 2026) - "Case Description/ A 54-year-old man with severe ulcerative pancolitis on infliximab (10 mg/kg every 8 weeks), 6-mercaptopurine, and mesalamine presented with a progressively enlarging ulcerative lesion on the dorsal left hand one month after travel to Thailand...Initial treatment with topical corticosteroids failed, and immunosuppression was escalated with oral prednisone, high-potency topical clobetasol, topical ruxolitinib, and increased infliximab dosing to every 6 weeks without improvement...The patient was started on oral itraconazole 200 mg twice daily, resulting in rapid and marked clinical improvement...Lack of response to standard PG therapy should prompt early biopsy with microbial cultures, particularly in immunosuppressed patients with relevant travel exposure. To our knowledge, this represents the first reported case of a rare presentation of cutaneous talaromycosis mimicking PG in an IBD patient on biologic therapy."

Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Pyoderma Gangrenosum • Ulcerative Colitis

Chronic Graft-Versus-Host Disease Following Intestine, Liver, Pancreas, and Stomach Transplantation (ACG 2026) - "Therapy escalates from everolimus and octreotide to capecitabine and temozolomide, with subsequent disease progression...Dermatology and hematology are consulted, topical steroids are started for the rash and tbo-filgrastim for worsening neutropenia...After refusing cytogam, he returns with rising CMV levels, is treated with IV ganciclovir, and discharged with oral valganciclovir...Persistent donor predominance on STR analysis with cutaneous and bone marrow involvement is shown. Treatment includes corticosteroids, etanercept, photopheresis, ruxolitinib, and supportive care."

Acute Graft versus Host Disease • Cardiovascular • Chronic Graft versus Host Disease • Cytomegalovirus Infection • Gastrointestinal Neuroendocrine Tumor • Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Leukopenia • Neuroendocrine Tumor • Neutropenia • Pulmonary Disease • Respiratory Diseases • Solid Organ Transplantation • Solid Tumor • Transplantation

Therapeutic expansion of JAK inhibitors in Chinese dermatological practice: beyond atopic dermatitis to novel autoimmune frontiers. (PubMed, Front Med (Lausanne)) - "Key clinical findings from rigorous trials indicate that oral tofacitinib achieves PASI75 in 58% of psoriatic patients within 16 weeks and topical ruxolitinib induces facial repigmentation exceeding 75% in vitiligo. In contrast, while current evidence is substantially limited to isolated case reports, emerging data suggest that baricitinib may resolve steroid-refractory BP lesions within one month...Crucially, we identify therapeutic gaps in segmental vitiligo and juvenile DM where clinical data are absent. This synthesis advocates for randomized controlled trials to validate JAKi efficacy against biologics in high-burden diseases currently dependent on glucocorticoids."

Journal • Review • Alopecia • Atopic Dermatitis • Bullous Pemphigoid • Cardiovascular • Chronic Spontaneous Urticaria • Dermatitis • Dermatology • Dermatomyositis • Dermatopathology • Hematological Disorders • Immunology • Myositis • Psoriasis • Thrombosis • Urticaria • Vitiligo • IFNG • IL23A • STAT3

Efficacy and Safety of Ruxolitinib Cream in Patients With Cutaneous Lichen Planus: A Randomized Clinical Trial. (PubMed, JAMA Dermatol) - P2 | "Therefore, ruxolitinib cream represents a potential treatment option for patients with cutaneous lichen planus. ClinicalTrials.gov Identifier: NCT05593432."

Clinical • Journal • Dermatology • Dermatopathology • Inflammation • Lichen Planus

Topical ruxolitinib for resistant dupilumab-associated facial dermatitis. (PubMed, Intern Med J) - No abstract available

Journal • Dermatitis • Dermatology • Immunology

A Review of Modern Therapies and New Innovations in the Treatment of Cutaneous Graft-versus-Host Disease. (PubMed, Dermatol Ther (Heidelb)) - "Recent advances in GVHD management have led to the introduction of targeted systemic agents, such as ruxolitinib, belumosudil, axatilimab, ibrutinib, and abatacept, each addressing different pathways implicated in disease pathogenesis and leading to incorporation into disease management based on established algorithms or select clinical contexts. Additionally, local immunomodulatory therapies, such as topical ruxolitinib, phototherapies, and extracorporeal photopheresis, can be utilized as adjunctive therapies for persistent or localized cutaneous disease. Cellular therapies, specifically mesenchymal stromal cells and regulatory T cells (Treg), are emerging therapies with promising potential in modulating the immune response and improving clinical outcomes. This review summarizes the current standards of care and recent therapeutic advances in the management of cutaneous GVHD, focusing on evidence-based therapies and skin-specific outcomes."

Journal • Review • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation

Current Management and Emerging Therapies for Pediatric Vitiligo: A Narrative Review. (PubMed, Paediatr Drugs) - "The approval of topical 1.5% ruxolitinib cream for individuals aged 12 years and older, following the demonstration of the drug's efficacy and safety, has prompted increased interest in emerging therapies for vitiligo. This article explores current topical treatments, phototherapy, and novel therapeutic approaches specifically in the pediatric and adolescent populations focusing on available published data. Additionally, we highlight the psychological impact of vitiligo on young patients and their families and emphasize practical considerations when managing this condition in this population."

Journal • Review • Dermatology • Immunology • Pediatrics • Vitiligo

Incyte to present skin disease data at EADV congress in Vienna (Streetinsider.com) - "Data on ruxolitinib cream, marketed as Opzelura, will feature across multiple atopic dermatitis sessions, including 24-week results from the TRuE-AD4 study examining long-term safety, pharmacokinetics, and patient-reported outcomes in adults with moderate atopic dermatitis. Additional posters will address comparative efficacy against systemic therapies and real-world data...Povorcitinib, an oral JAK1 selective inhibitor under regulatory review in both the U.S. and Europe as a potential treatment for moderate to severe hidradenitis suppurativa, will be the subject of pooled Phase 3 data from the STOP-HS1 and STOP-HS2 studies. A poster will also present data on its use in nonsegmental vitiligo....Presentations on prurigo nodularis will include epidemiological data on incidence, prevalence, and treatment patterns in the U.S. and Germany."

Clinical data • P3 data • Atopic Dermatitis • Hidradenitis Suppurativa • Immunology • Prurigo Nodularis • Vitiligo

Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial. (PubMed, Lancet Haematol) - P2 | "Topical ruxolitinib showed significant clinical activity and favourable harms profile in active cutaneous cGVHD. Ruxolitinib cream could represent a steroid-sparing, skin-directed alternative or second-line therapy, expanding treatment options for patients with cutaneous cGVHD."

Journal • P2 data • Acute Graft versus Host Disease • Atopic Dermatitis • Chronic Graft versus Host Disease • Critical care • Dermatitis • Dermatology • Graft versus Host Disease • Hematological Malignancies • Immunology • Infectious Disease • Leukemia • Oncology • Otorhinolaryngology • Respiratory Diseases • Sinusitis • Transplantation • Vitiligo

Translating ruxolitinib cream data for moderate AD into clinical practice (EADV 2026) - "This session is sponsored by: Incyte Biosciences International Sàrl"

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology

TOPICAL RUXOLITINIB IN NON-SEGMENTAL VITILIGO: REAL-WORLD OUTCOMES IN TERTIARY HOSPITAL SETTING (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Vitiligo

Long-term real-world effectiveness of ruxolitinib cream in vitiligo: a multimodal assessment combining clinical outcomes, quality of life, and confocal microscopy (EADV 2026) - No abstract available

Clinical • Clinical data • HEOR • Real-world • Real-world effectiveness • Real-world evidence • Dermatology • Immunology • Vitiligo

Early high-resolution dermoscopic features predict response to topical ruxolitinib in nonsegmental vitiligo (EADV 2026) - No abstract available

Dermatology • Immunology • Vitiligo

Pruritus as a Primary Endpoint, not a Symptom: Reconciling Discrepant Phase 3 Placebo Responses in Prurigo Nodularis (Ruxolitinib Cream) to Decode the Placebo-Activated Neural Pathway (EADV 2026) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Prurigo Nodularis • Pruritus

Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura) in Australia (PRNewswire) - "Under the terms of the expanded agreement, Incyte will remain responsible for the development and manufacturing of ruxolitinib cream, while ST will manage regulatory submissions, medical affairs, marketing, and distribution across Australia....ST anticipates progressing regulatory and reimbursement submissions for OPZELURA with Australian healthcare authorities in due course."

Licensing / partnership • Atopic Dermatitis • Vitiligo

Ruxolitinib Cream Use to Delay or Prevent Treatment Escalation in Adults With Moderate Atopic Dermatitis Eligible for Systemic Therapy: Results From the TRuE-AD4 Study (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Ruxolitinib Cream in Moderate Atopic Dermatitis Across Disease Severity Thresholds: Insights From Randomized Trials and Real-World Data (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Product Theater 3 (non-CME) - Incyte : Managing MILD TO MODERATE ATOPIC DERMATITIS: Expanding Treatment Options for Patients with a Topical JAK Inhibitor (ACAAI 2026) - "Sponsored by Incyte Description This presentation discusses the burden of atopic dermatitis and introduces OPZELURA® (ruxolitinib) cream 1.5% as a topical, non-steroidal JAK inhibitor. It highlights clinical trial data demonstrating rapid itch relief and skin clearance in adult and pediatric patients aged 2 years and older with mild to moderate atopic dermatitis. Also visit Incyte at Booth #1124."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Utilization, cost, and specialty distribution of topical ruxolitinib prescribing in Medicare Part D, 2018-2024: A cross-sectional study. (PubMed, JAAD Int) - No abstract available

Journal • Medicare • Observational data • Reimbursement • US reimbursement • Atopic Dermatitis • Dermatitis • Dermatology • Vitiligo

Clinical Response to Topical Ruxolitinib in Refractory Papulopustular Rosacea: A Case Series. (PubMed, Int J Dermatol) - No abstract available

Journal • Dermatology • Rosacea

Real world clinical improvement and drug use in patients with non-segmental vitiligo treated with ruxolitinib cream. (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Dermatology • Immunology • Vitiligo

Efficacy and Safety of Topical 1.5% Ruxolitinib Cream For Treatment of Chronic Hand Eczema, Head and Neck Dermatitis, and Prurigo Nodularis in a Cohort of Asian Patients with Atopic Dermatitis (EADV 2026) - No abstract available

Clinical • Contact Dermatitis • Dermatitis • Dermatology • Immunology • Prurigo Nodularis

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo (clinicaltrials.gov) - P3 | N=180 | Recruiting | Sponsor: Incyte Corporation | Trial completion date: Mar 2027 ➔ Dec 2028 | Trial primary completion date: Aug 2026 ➔ Jun 2028

Trial completion date • Trial primary completion date • Dermatology • Immunology • Pediatrics • Vitiligo

Quality-of-Life Impairment and Impact of Treatment in an Open-Label, Phase 2 Study of Ruxolitinib Cream in Patients With Genital Vitiligo (EADV 2026) - No abstract available

Clinical • HEOR • P2 data • Dermatology • Immunology • Vitiligo

Efficacy and Safety of Combined Home-Use 308-nm Phototherapy for Non-Facial Vitiligo Lesions Treated with Topical JAK Inhibitors (ChiCTR) - P4 | N=46 | Recruiting | Sponsor: The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University

New P4 trial • Dermatology • Immunology • Vitiligo